Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
38 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
21
21 articles ont été cités au moins 21fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
2 877
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
96
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
35
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Assistance Publique – Hôpitaux de Paris · Hôpital Européen
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Clinical and Pathological Features of EC-cell Familial Small Intestine Neuroendocrine Tumors: A Nationwide Cohort From the French GTE-RENATEN Network
2026ArticleEndocrine Pathology
Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study
2025ArticleJNCI: Journal of the National Cancer Institute
Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study
2025ArticleOncologist
Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials
2025ArticleJournal of Clinical Oncology
Progression of carcinoid heart disease in the modern management era
2021ArticleJournal of the American Heart Association
Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial
2021ArticleClinical Cancer Research
Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data
2020ArticleStatistical Methods in Medical Research
Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study
2019ArticleEuropean Journal of Cancer
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP CUP SITE G POMPIDOU HEGP
20 R LEBLANC, 75908 PARIS CEDEX 15
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
Purpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III colon cancer. This could offer clear advantages to patients and health care providers. Methods In International Duration Evaluation of Adjuvant Chemotherapy (IDEA) France, as part of the IDEA international collaboration, patient with colon cancer patients were randomly assigned to 3 and 6 months of modified FOLFOX6 (mFOLFOX6: infusional fluorouracil, leucovorin, and oxaliplatin) or capecitabine plus oxaliplatin (CAPOX) by physician choice. The primary end point was disease-free survival (DFS), and analyses were descriptive. Results A total of 2,010 eligible patients received either 3 or 6 months of chemotherapy (modified intention-to-treat population); 2,000 (99%) had stage III colon cancer (N1: 75%, N2: 25%); 1,809 (90%) received mFOLFOX6, and 201 (10%) received CAPOX. The median age was 64 years, and the median follow-up time was 4.3 years. Overall, 94% (3 months) and 78% (6 months) of patients completed treatment (fluoropyrimidines ± oxaliplatin). Maximal grade 2 and 3 neuropathy rates were 28% and 8% in the 3-month arm and 41% and 25% in the 6-month arm ( P < .001). Final rates of residual neuropathy greater than grade 1 were 3% in the 3-month arm and 7% in the 6-month arm ( P < .001). There were 578 DFS events: 314 and 264 in the 3- and 6-month arms, respectively. The 3-year DFS rates were 72% and 76% in the 3- and 6-month arms, respectively (hazard ratio [HR], 1.24; 95% CI, 1.05 to 1.46; P = .0112). In the 3 and 6-month arms, respectively, for patients who received mFOLFOX6, the 3-year DFS rates were 72% and 76% (HR, 1.27; 95% CI, 1.07 to 1.51); for the T4 and/or N2 population, they were 58% and 66% (HR, 1.44; 95% CI, 1.14 to 1.82); and for the T1-3N1 population, they were 81% and 83% (HR, 1.15; 95% CI, 0.89 to 1.49). Conclusion IDEA France, in which 90% of patients received mFOLFOX6, shows superiority of 6 months of adjuvant chemotherapy compared with 3 months, especially in the T4 and/or N2 subgroups. These results should be considered alongside the international IDEA collaboration data.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
Abstract Purpose: Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage-III colon cancer. We analyzed ctDNA of patients randomized in the phase III IDEA-France trial. Experimental Design: ctDNA was tested for WIF1 and NPY by droplet digital PCR with method developed and validated for colorectal cancer. Disease-free survival (DFS) and overall survival (OS) were analyzed via multivariable analysis in patients with ctDNA samples and in sub-groups according to treatment duration (3/6 months) and disease stage (high/low-risk stage III). Results: Of 2,010 randomized patients, 1,345 had available ctDNA samples (1,017 collected both post-surgery and pre-chemotherapy). More Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 (78% versus 69%) and T4 and/or N2 (40% versus 36%) were observed in patients studied (n = 1017) versus not analyzed (n = 993). There were 877 ctDNA-negative (86.2%) and 140 ctDNA-positive (13.8%) patients; their baseline characteristics were similar. With a median follow-up of 6.6 years, the 3-year DFS rate was 66.39% for ctDNA-positive patients and 76.71% for ctDNA-negative patients (P = 0.015). ctDNA was confirmed as an independent prognostic marker for DFS (adjusted HR = 1.55, 95% CI 1.13–2.12, P = 0.006) and OS (HR = 1.65, 95% CI 1.12–2.43, P = 0.011). ctDNA was prognostic in patients treated for 3 months and with T4 and/or N2 tumors, but not in those treated for 6 months and with T1–3/N1 tumors. Conclusions: In this first ctDNA assessment of a large series of patients with stage III colon cancer enrolled in phase III trial, post-surgery ctDNA was found in 13.8% of them and was confirmed as an independent prognostic marker. See related commentary by Bent and Kopetz, p. 5449
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Endocrine pathology · 2026 · Journal Article
Hunaut T, Gérard L, Hercent A, Hentic O, et al.
Journal of the National Cancer Institute · 2025 · Journal Article
Zaanan A, Bergen ES, Evesque L, Meurisse A, et al.
The oncologist · 2025 · Journal Article
Evrard C, Pelras A, Rivet S, Bachet JB, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · Journal Article
Taieb J, Souglakos J, Boukovinas I, Falcoz A, et al.
Journal of the American Heart Association · 2021 · Journal Article
Baron E, Szymanski C, Hergault H, Lepère C, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2021 · Clinical Trial, Phase III
Taieb J, Taly V, Henriques J, Bourreau C, et al.
Statistical methods in medical research · 2020 · Journal Article
Boulet S, Ursino M, Thall P, Landi B, et al.
British journal of cancer · 2018 · Clinical Study
Pernot S, Dubreuil O, Aparicio T, Le Malicot K, et al.
Clinics and research in hepatology and gastroenterology · 2018 · Journal Article
Pernot S, Velut G, Kourie RH, Amouyal G, et al.
European journal of cancer (Oxford, England : 1990) · 2016 · Journal Article
Bouchahda M, Boige V, Smith D, Karaboué A, et al.
Therapeutic advances in medical oncology · 2016 · Journal Article
Dréanic J, Lepère C, El Hajjam M, Gouya H, et al.
Medicine · 2015 · Comparative Study
Brieau B, Lepère C, Walter T, Lecomte T, et al.
British journal of cancer · 2015 · Journal Article
Portal A, Pernot S, Tougeron D, Arbaud C, et al.
La Revue du praticien · 2015 · English Abstract
Pointet AL, Lepère C, Taieb J
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2014 · Journal Article
Lièvre A, Laurent V, Cudennec T, Peschaud F, et al.
Clinics and research in hepatology and gastroenterology · 2014 · Case Reports
Portal A, Pernot S, Siauve N, Landi B, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2014 · Journal Article
Touchefeu Y, Archambeaud I, Landi B, Lièvre A, et al.
Clinics and research in hepatology and gastroenterology · 2013 · Journal Article
Boussaha T, Rougier P, Taieb J, Lepere C
Clinics and research in hepatology and gastroenterology · 2013 · Case Reports
Auclin E, Camiliéri C, Dubreuil O, Lepère C, et al.
Clinics and research in hepatology and gastroenterology · 2011 · Journal Article
Trouilloud I, Dubreuil O, Boussaha T, Lepère C, et al.
World journal of gastroenterology · 2010 · Case Reports
Neuzillet C, Lepère C, El Hajjam M, Palazzo L, et al.
BMC cancer · 2009 · Journal Article
Lièvre A, Samalin E, Mitry E, Assenat E, et al.
Gastroenterologie clinique et biologique · 2007 · Journal Article
Mitry E, Taleb-Fayad R, Deschamps A, Mansencal N, et al.
Gastroenterologie clinique et biologique · 2007 · Case Reports
Lepère C, Rakotomalala S, Maindrault-Goebel F, Mitry E, et al.
Gastroenterologie clinique et biologique · 2007 · Journal Article
Bachet JB, Mitry E, Lepère C, Declety G, et al.
American heart journal · 2006 · Journal Article
Mansencal N, Mitry E, Forissier JF, Martin F, et al.
Seminars in oncology · 2005 · Journal Article
Rougier P, Lepere C
Seminars in oncology · 2005 · Journal Article
Rougier P, Lepère C
Gastrointestinal endoscopy · 2005 · Comparative Study
Lepère C, Cuillerier E, Van Gossum A, Bezet A, et al.
European journal of cancer (Oxford, England : 1990) · 2019 · Clinical Trial, Phase II
Walter T, Lepage C, Coriat R, Barbier E, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018 · Clinical Trial, Phase III
André T, Vernerey D, Mineur L, Bennouna J, et al.
Clinics and research in hepatology and gastroenterology · 2025 · Letter
Besson A, Gallois C, Lepere C, Netter J, et al.
Clinics and research in hepatology and gastroenterology · 2013 · Case Reports
Brieau B, Roussel H, Markoutsaki T, Dubreuil O, et al.
The American journal of cardiology · 2008 · Clinical Trial
Mansencal N, Mitry E, Pillière R, Lepère C, et al.
European journal of cancer (Oxford, England : 1990) · 2017 · Clinical Trial, Phase III
Aparicio T, Gargot D, Teillet L, Maillard E, et al.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2014 · Journal Article
Pernot S, Mitry E, Samalin E, Dahan L, et al.
Clinics and research in hepatology and gastroenterology · 2025 · Letter
Besson A, Gallois C, Lepere C, Netter J, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2018 · Clinical Trial, Phase II
Walter T, Malka D, Hentic O, Lombard-Bohas C, et al.
European journal of cancer (Oxford, England : 1990) · 2017 · Clinical Trial, Phase III
Aparicio T, Gargot D, Teillet L, Maillard E, et al.
European journal of cancer (Oxford, England : 1990) · 2014 · Clinical Trial, Phase II
Ducreux M, Dahan L, Smith D, O'Toole D, et al.